Primary lymphoproliferative diseases of the central nervous system


Cite item

Full Text

Abstract

Primary CNS lymphomas have worse prognosis than other extranodal lymphomas: remissions are rare, recurrences are frequent. Literature is analysed on diagnosis, prognostic factors, perspectives and problems of treatment of primary CNS lymphomas.

References

  1. Russell D. S., Rubinstein L. J. Nervous system involvement by lymphomas, histiocytoses, and lenkemias. In: Pathology of tumours of the nervous system. 5-th ed. London: Edward Arnold; 1998. 195-237.
  2. Kadan-Lottick N. S., Skluzarek M. C., Gurney J. G. Decreasing incidence rates of primary central nervous system lymphoma. Cancer 2002; 95: 193-202.
  3. Henry J. M., Heffner R. R. J., Dillard S. H. et al. Primary malignant lymphomas of the central nervous system. Cancer 1974; 34: 1293-1302.
  4. O'Neill B. P., Illig J. J. Primary central nervous system lymphoma. Mayo Clin. Proc. 1989; 64: 1005-1020.
  5. Губкин А. В., Звонков Е. Е. и др. Первичные лимфопролиферативные заболевания центральной нервной системы. Клин. онкогематол. 2009; 1: 26-32.
  6. Iwamoto F. M., Abrey L. E. Primary dural lymphomas: a review. Neurosurg. Focus 2006; 21 (5): E5.
  7. Gobbato P. L., de Azambuja Pereira Filho A. et al. Primary meningeal burkitt-type lymphoma presenting as the first clinical manifestation of acquired immunodeficiency syndrome. Arq. Neuropsiquiatr. 2006; 64 (2-B): 511-515.
  8. Carole Soussain, Khe Hoang-Xuan, Doolittle N. D. New treatment approaches in pcnsl. Haematol Oncol. Clin. N. Am. 2005; 19: 719-728.
  9. Shah G. D., Yahalom J., Correa D. D. et al. Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma. J. Clin. Oncol. Orig. Rep. 2007; 25 (30): 4730-4735.
  10. Miller D. C., Hochberg F. H., Harris N. L. et al. Pathology with clinical correlations of primary central nervous system non-Hodgkin's lymphoma. The Massachusetts General Hospital experience 1958-1998. Cancer 1998; 74: 1383-1397.
  11. MacMahon E. M. E., Glass J. D., Hayward S. D. et al. Epstein-Barr virus in AIDS-related primary central nervous system lymphoma. Lancet 1999; 338: 969-973.
  12. Ferreri A. J., Reni M., Villa E. Primary central nervous system lymphoma in immunocompetent patients. Cancer Treat. Rev. 1995; 21: 415-446.
  13. Bataille B., Delwail V., Menet E. et al. Primary intracerebral malignant lymphoma: A report of 248 cases. J. Neurosurg. 2000; 92: 261-266.
  14. Henson J. W., Batchelor T. T. Intraocular lymphoma. In: Batchelor T. T., ed. Lymphoma of the nervous system. Boston, MA: Butterworth-Heinemann; 2004. 183-188.
  15. Ferreri J. M., Blay J.-Y., Reni M. et al. Relevance of intraocular involvement in the management of primary central nervous system lymphomas. Ann. Oncol. 2002; 13: 531-538.
  16. Jellinger K. A., Paulus W. Primary central nervous system lymphomas-an update. J. Cancer Res. Clin. Oncol. 1992; 119: 7- 27.
  17. Hayakawa T., Takakura K., Abe H. et al. Primary central nervous system lymphoma in Japan - a retrospective, cooperative study by CNS-Lymphoma Study Group in Japan. J. Neurooncol. 1994; 19: 197-215.
  18. Fine H. A., Mayer R. J. Primary central nervous system lymphoma. Ann. Intern. Med. 1993; 119: 1093-1104.
  19. Воробьев А. И., Бриллиант М. Д. Лимфосаркомы. В кн.: Воробьев А. И. (ред.). Руководство по гематологии. М.: Медицина; 1985; т. 1: 336-337.
  20. Воробьев А. И., Кременецкая А. М. (ред.). Атлас. Опухоли лимфатической системы. М.: Ньюдиамед; 2007. 167-171.
  21. Гейманович З. И., Смирнов Л. И. Опухоли центральной нервной системы. Киев: Гос. мед. изд-во УССР; 1936.
  22. Jellinger K. A., Paulus W. Primary central nervous system lymphomas-new pathological developments. J. Neurooncol. 1995; 24: 33-36.
  23. Авцын А. П., Виккерт Т. М., Касумова С. Ю. Интернациональная гистологическая классификация опухолей центральной нервной системы. Журн. вопр. нейрохир. 1981; 2: 45-51.
  24. Keller A. R., Hochholzer L., Castleman B. Hyaline-vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locations. Cancer 1972; 670-683.
  25. Schwechheimer K., Schwarzkopf G., Braus D. et al. Primary cerebral malignant non-Hodgkin's lymphomas. Histological and immunopathological findings on stereotactic brain biopsies. Clin. Neuropathol. 1989; 8: 250-251.
  26. Matano S., Nakamura S., Ohtake S. et al. Primary T-cell non-Hodgkin's lymphoma of the central nervous system. Case report and review of the literature. Acta Haematol. 1994; 91: 158-163.
  27. Lister A., Abrey L. E., Sandlund J. T. Central nervous system lymphoma. Hematology 2002; 1: 283-296.
  28. Hansen P. B., Penkowa M., Kirk O. et al. Human immunodeficiensy virus-associated malignant lymphoma in eastern Denmark diagnosed from 1990-1996: clinical features, histopathology, and association with Epstein-Barr virus and human herpesvirus-8. Eur. J. Haematol. 2000; 64: 368-375.
  29. Kumanishi T., Zhang S., Ichikawa T. et al. Primary malignant lymphoma of the brain: demonstration of frequent p16 and p15 gene deletions. Jpn J. Cancer Res. 1996; 87: 691-695.
  30. Reni M., Ferreri A. J., Zoldan M. C., Villa E. Primary brain lymphomas in patients with a prior or concomitant malignancy. J. Neurooncol. 1997; 32: 135-142.
  31. Воробьев А. И., Кременецкая А. М., Лорис Ю. Ю. и др. "Старые" и "новые" опухоли лимфатической системы. Тер. арх. 2000; 7: 9-14.
  32. Ferreri A. J., Reni M., Zoldan M. C. et al. Importance of complete staging in non-Hodgkin's lymphoma presenting as a cerebral mass lesion. Cancer 1996; 77: 827-833.
  33. Pollack I. F., Lunsford L. D., Flickinger J. C., Dameshek H. L. Prognostic factors in the diagnosis and treatment of primary central nervous system lymphoma. Cancer 1989; 63: 939-947.
  34. Ferreri A. J., Blay J. Y., Reni M. Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. J. Clin. Oncol. 2003; 21 (2): 266-272.
  35. Круглова Г. В., Абдулбаев Р. А., Финогенова И. А., Тарасюк С. В. Лечение и прогноз поражения центральной нервной системы при лимфосаркоме. Тер. арх. 1983; 55 (8): 36-40.
  36. Boiardi A., Sylvani A., Valentini S. et al. Chemotherapy as first treatment for primary malignant non-Hodgkin's lymphoma of the central nervous system preliminary data. J. Neurol. 1993; 241: 96-100.
  37. DeAngelis L. M., Yahalom J., Thaler H. T., Kher U. Combined modality therapy for primary CNS lymphoma. J. Clin. Oncol. 1992; 10: 635-643.
  38. Kikuchi K., Watanabe K., Miura S., Kowada M. Steroid-induced regression of primary malignant lymphoma of the brain. Surg. Neurol. 1996; 26: 291-296.
  39. DeAngelis L. M., Yahalom J., Heinemann M. H. et al. Primary CNS lymphoma: combined treatment with chemotherapy and radiotherapy. Neurology 1990; 40: 80-86.
  40. Shibamoto Y., Tsutsui K., Dodo Y. et al. Improved survival rate in primary intracranial lymphoma treated by high- dose radiation and systemic vincristine-doxorubicin-cyclophosphamide- prednisolone chemotherapy. Cancer 1990; 65: 1907-1912.
  41. Chamberlain M. C., Levin V. A. Adjuvant chemotherapy for primary lymphoma of the central nervous system. Arch. Neurol. 1990; 47: 1113-1116.
  42. Ferreri A. J., Reni M., Bolognesi A. et al. Combined therapy for primary central nervous system lymphoma in immunocompetent patients. Eur. J. Cancer 1995; 31 A: 2008-2012.
  43. Glass J., Gruber M. L., Cher L., Hochberg F. H. Preirradiation methotrexate chemotherapy of primary central nervous system lymphoma: long-term outcome. J. Neurosurg. 1994; 81: 188-195.
  44. Cher L., Glass J., Harsh G. R., Hochberg F. H. Therapy of primary CMS lymphoma with methotrexate-based chemotherapy and deferred radiotherapy: preliminary results. Neurology 1996; 46: 1757-1759.
  45. O'Brien P. C., Roos D. E., Liew K. H. et al. Preliminary results of combined chemotherapy and radiotherapy for non-AIDS primary central nervous system lymphoma. Trans-Tasman Radiation Oncology Group (TROG). Med. J. Aust. 1996; 165: 424-427.
  46. Guha-Thakurta N., Damek D., Pollack C., Hochberg F. H. Intravenous methotrexate as initial treatment for primary central nervous system lymphoma: response to therapy and quality of life of patients [In Process Citation]. J. Neurooncol. 1999; 43: 259-268.
  47. Blay J. Y., Bouhour D., Carrie C. et al. The C5R protocol: a regimen of high-dose chemotherapy and radiotherapy in primary cerebral non-Hodgkin's lymphoma of patients with no known cause of immunosuppression [see comments]. Blood 1995; 86: 2922-2929.
  48. Bessell E. M., Punt J., Firth J. et al. Primary non-Hodgkin's lymphoma of the central nervous system: phase II study of chemotherapy (BVAM) prior to radiotherapy. Clin. Oncol. (R. Coll. Radiol.) 1991; 3: 193-198.
  49. Glass J., Shustik C., Hochberg F. H. et al. Therapy of primary central nervous system lymphoma with pre-irradiation methotrexate, cyclophosphamide, doxorubicin, vincristine, and dexamethasone (MCHOD). J. Neurooncol. 1996; 30: 257-265.
  50. Korfel A., Thiel E. Successful treatment of non-Hodgkin's lymphoma of the central nervous system with BMPD chemotherapy followed by radiotherapy. Leukemia and Lymphoma. 1998; 30: 609-617.
  51. Brada M., Hjiyiannakis D., Hines F. et al. Short intensive primary chemotherapy and radiotherapy in sporadic primary CNS lymphoma (PCL). Int. J. Radiat. Oncol. Biol. Phys. 1998; 40: 1157-1162.
  52. Blay J. Y., Conroy T., Chevreau C. et al. High-dose methotrexate for the treatment of primary cerebral lymphomas: analysis of survival and late neurologic toxicity in a retrospective series. J. Clin. Oncol. 1998; 16: 864-871.
  53. O'Neill B. P., O'Fallon J. R., Earle J. D. et al. Primary central nervous system non-Hodgkin's lymphoma: survival advantages with combined initial therapy? [see comments]. Int. J. Radiat. Oncol. Biol. Phys. 1995; 33: 663-673.
  54. Schultz C., Scott C., Sherman W. et al. Preirradiation chemotherapy with cyclophospharnide, doxorubicin, vincristine, and dexamethasone for primary CMS lymphomas: initial report of radiation therapy oncology group protocol 88-06. J. Clin. Oncol. 1996; 14: 556-564.
  55. Bessell E. M., Graus F., Punt J. A. et al. Primary non-Hodgkin's lymphoma of the CNS treated with BVAM or CHOD/ BVAM chemotherapy before radiotherapy. J. Clin. Oncol. 1996; 14: 945-954.
  56. Camilleri-Broet S., Martin A., Moreau A. et al. Primary central nervous system lymphomas in 72 immunocompetent patients: pathologic findings and clinical correlations. Groupe Quest Est d'etude des Leucenies et Autres Maladies du Sang (GOELAMS). Am. J. Clin. Pathol. 1998; 110: 607-612.
  57. Dorreen M. S., Ironside J. W., Bradshaw J. D. et al. Primary intracerebral lymphoma: a clinicopathological analysis of 14 patients presenting over a 10-year period in Sheffield. Quart. J. Med. 1988; 67: 387-404.
  58. Davey P., Catton C., Ngan B., Whitton A. Phase I study of hyperfractionated whole brain irradiation (HWBI) in the treatment of primary cerebral lymphoma. Clin Oncol. (R. Coll. Radiol.) 1993; 5 (3): 159-164.
  59. Sandor V., Stark-Vanes V., Pearson D. et al. Phase II trial of chemotherapy alone for primary CNS and intraocular lymphoma. J. Clin. Oncol. 1998; 16: 3000-3006.
  60. Chamberlain M. C., Kormanik P. A., Barba D. Complications associated with intraventricular chemotherapy in patients with leptomeningeal metastases. J. Neurosurg. 1997; 87 (5): 694-699.
  61. Lishner M., Perrin R. G., Feld R. et al. Complications associated with Ommaya reservoirs in patients with cancer. The Princess Margaret Hospital experience and a review of the literature. Department of Medicine, Ontario Cancer Institute, Toronto, Canada. Arch. Intern. Med. 1990 Jan; 150 (1): 173-176.
  62. Gubkin A. et al. TioThepa, BCNU, VM-26, Dexamethasone, and High-dose Methotrexate (TioCaTeMeD) as therapy for Primary CNS Lymphoma (PCNSL). Ann. Oncol. 2002; 13 (suppl. 2: Abstract 8th International conference on malignant lymphoma): 125.
  63. Abrey L. E., Ben-Porat L., Panageas K. S. et al. Primary central nervous system lymphoma: The Memorial Sloan-Kettering Cancer Center Prognostic Model. J. Clin. Oncol. 2006; 24 (36): 5711-5715.
  64. Rubenstein I. L., Combs D., Kosenberg I. et al. Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. Blood 2003; 101 (2): 466-448.
  65. Pels H., Schulz H., Manzke O. et al. Intraventricular and intravenous treatment of a patient with refractory primary CNS lymphoma using rituximab. J. Neurooncol. 2002; 59 (3): 213-216.
  66. Gubkin A., Nikolaeva T. et al. Mabtera in the treatment of primary CNS lymphomas (PCNSL). Ann. Oncol. 2002; 13 (suppl. 2: Abstract 8-th International conference on malignant lymphoma): 125.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2009 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies